Company: EDSA
Filing Date: 2025-03-11
Form Type: 424B3
Source: 0001171843-25-001403
Chunk: 11

Company: Edesa Biotech, Inc.
Filing Date: 2025-03-11
Form: 424B3
Chunk 11
---
, as a Managing Member of each of Velan GP and Velan IM GP, may be deemed to beneficially own the 
 shares beneficially owned by Velan Opp Fund II. Adam Morgan, as the Chief Investment Officer of Velan Capital and a Managing Member of  
 each of Velan GP and Velan IM GP, may be deemed to beneficially own the shares beneficially owned by Velan Opp Fund II.                 |

| (18) |     | Includes (i) 250,000 Shares purchased in the Private Placement                                           
 and (ii) 1,015,625 Conversion Shares underlying the Preferred Shares purchased in the Private Placement. |

| (19) |     | Nantahala Capital Management, LLC is a Registered Investment                                                                                 
 Adviser and has been delegated the legal power to vote and/or direct the disposition of such securities on behalf of the Selling Shareholder 
 as a General Partner, Investment Manager, or Sub-Advisor and would be considered the beneficial owner of such securities. The above shall    
 not be deemed to be an admission by the record owners or the Selling Shareholder that they are themselves beneficial owners of these         
 securities for purposes of Section 13(d) of the Exchange Act or any other purpose. Wilmot Harkey and Daniel Mack are managing members        
 of Nantahala Capital Management, LLC and may be deemed to have voting and dispositive power over the shares held by the Selling Shareholder. |

| (20) |     | Includes (i) 178,167 Shares purchased in the Private Placement                                         
 and (ii) 119,792 Conversion Shares underlying the Preferred Shares purchased in the Private Placement. |

| (21) |     | Includes (i) 100,613 Shares purchased in the Private Placement                                        
 and (ii) 67,708 Conversion Shares underlying the Preferred Shares purchased in the Private Placement. |

| (22) |     | Includes (i) 346,220 Shares purchased in the Private Placement                                         
 and (ii) 229,167 Conversion Shares underlying the Preferred Shares purchased in the Private Placement. |

| (23) |     | Stonepine Capital Management, LLC (“Stonepine”)                                                                                        
 and Stonepine GP, LLC (“Stonepine GP”) are the investment adviser and general partner, respectively, of Stonepine Capital,             
 LP. (“Stonepine Partnership”). Jon Plexico is the control person of Stonepine and Stonepine GP. Stonepine, Stonepine GP,               
 Stonepine Partnership and Mr. Plexico disclaim beneficial